Clinical Evidence

Our clinical programs are leading the field

Explore the scientific evidence supporting GRAIL’s multi-cancer early detection approach, including peer-reviewed publications and presentations at leading medical congresses. Together, these data highlight test performance, clinical utility, and progress toward transforming cancer screening.

Manuscripts

Out-of-pocket cost by cancer stage at diagnosis in commercially insured patients in the United States

View Manuscript
grail stock aug2025 21
Lancet

Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study

View Manuscript
BMC Health Services Research

The aggregate value of cancer screenings in the United States: full potential value and value considering adherence

View Manuscript
BMJ Open

Psychological Impact of the Galleri test (sIG(n)al): protocol for a longitudinal evaluation of the psychological impact of receiving a cancer signal in the NHS-Galleri trial

View Manuscript
JCO Precision Oncology

Performance of a Cell-Free DNA-Based Multi-cancer Detection Test in Individuals Presenting With Symptoms Suspicious for Cancers

View Manuscript
screenshot 2025 08 19 at 9.24.46 am
Lancet Oncology

Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study

View Manuscript

Presentations